Carmignac

Carmignac Portfolio Patrimoine Europe: Letter from the Fund Manager

  • +1.60%
    Carmignac Portfolio Patrimoine Europe’s performance

    in the 4th quarter of 2022 for the A EUR Share class.

  • +3.39%
    Reference indicator¹’s performance

    in the 4th quarter of 2022.

  • +22.92%
    Performance of the Fund over 5 years

    vs +11.21% for the reference indicator (A EUR Share class).

Carmignac Portfolio Patrimoine Europe A EUR Acc gained +1.60% in the fourth quarter of 2022, underperforming the +3.39% rise of its reference indicator¹

European Markets Review

In line with this year, the fourth quarter was marked by significant volatility in both European equity and fixed income markets.

At the beginning of the period, European equities experienced a significant rebound, with the Stoxx 600 Europe increasing by 15% within two months. This was largely due to investor anticipation of less restrictive monetary policy from central bankers amid concerns about economic growth, leading to an increase in risky assets and a stabilization in interest rates.

However, inflation continued to rise and reached a record high of 10.6% in Eurozone, a level not seen since the 1980s. In response to this unprecedented challenge, Christine Lagarde maintained her monetary tightening stance and implemented two interest rate hikes (+125 bps over the quarter) and reaffirmed her commitment to combat inflation. This communication, aligned with the statements of the Fed, put an end to the fall rebound. Consequently, growth stocks suffered while core rates reached new highs in Europe, closing the quarter at their peak in over 10 years.

Quarterly Performance Review

In this context, the Fund maintained a conservative portfolio construction during the quarter by being prudently exposed to equities while actively managing interest rate exposures. If this positioning helped to reduce the volatility, it prevented the Fund from fully participating in the strong rebound at the beginning of the quarter.12

Despite this relative underperformance, our underlying equity portfolio performed positively during the quarter led by the healthcare sector. The adjustments we made to the portfolio, including increasing our holdings in Novo Nordisk and Genmab, seem to be paying off as these stocks achieved double digit returns in a slightly more favorable environment. On the credit side, the Fund suffered both from its protection on the high yield segment and from its bond selection that has been affected by idiosyncratic events.

Outlook

Following a year characterised by the resurgence of inflation, we anticipate that the markets will face two uncertainties in 2023:

  • Will there be further increases in interest rates?
  • How will monetary policies affect economic growth and company earnings?

Our view at the moment is that European growth will slow down in 2023, with a mild decline during the first half of the year followed by a slight increase later on. However, the latest economic data hint towards a more resilient growth than expected at least for Q4 2022. At the same time, headline inflation figures in Europe may be difficult to accurately determine due to the varied support plans for governments, but it is expected that core inflation will remain high, around 5%. These 2 aspects could support the ECB in pursuing its stance at least during the first semester to curb inflation. In terms of company profits, we believe that the forecasted flat earnings growth next year is still optimistic and carries downside risk, particularly in economically sensitive sectors. Conversely, fixed income is by far the asset class that’s been the most affected by central banks’ aggressive tightening actions, making it more appealing.

In this context, the fund's performance drivers are as follows:

  • In 2022, equity markets have already seen a significant contraction in valuation multiples hurting our stock selection, but they are still far from fully considering the potential impact of a recession on earnings. As a result, we favor high-quality companies which are likely to capitalize on their robust fundamentals to surpass the average rate of earnings growth. We focus our portfolio on companies and sectors best able to withstand a slowdown as healthcare or consumer staples and we benefited from price dislocation this year to add new names at attractive price such as Genmab or Lonza.

  • Unlike equity markets, corporate bond current valuations are mostly reflecting poor growth sentiment, providing a great income profile with a lot of bad news already priced in. We see value in credit markets but advocate an actively managed approach. As such, we begin the year with a 10% exposure to this asset class before gradually increasing it.

  • As we have not yet fully emerged from the challenges of economic growth and inflation, volatility in stocks and bonds is likely to remain high and will require short-term tactical adjustments to exploit these movements via active modified duration management and equity hedging.

    While gloomy on the surface, the market environment has never been so full of both risks and opportunities. The end of extraordinary monetary policies means the end of indiscriminate market increases, and the potential of true alpha generation thanks to selective and active management. The end of negative interest rates and asset class correlation as we know it reinforces the importance of a flexible allocation to optimize performance. Finally, the return of volatility means the need for an active management of risks, to protect the book’s long-term opportunities.

Source: Carmignac, Bloomberg, 31/12/2022. Performance of the A EUR Acc share class ISIN code: LU1744628287. ¹Reference Indicator: 40% STOXX Europe 600 (Reinvested Net Dividends) + 40% ICE BofA All Maturity All Euro Government + 20% ESTER capitalized. Quarterly Rebalanced. Until 31/12/2021, the reference indicator was 50% STOXX Europe 600, 50% BofA Merrill Lynch All Maturity All Euro Government Index. The performances are presented using the chaining method. Risk Scale from the KID (Key Investor Information Document). Risk 1 does not mean a risk-free investment. This indicator may change over time. *Launch date: 29/12/2017.

Carmignac Portfolio Patrimoine Europe

An all-weather European Fund

Discover the fund page

Carmignac Portfolio Patrimoine Europe A EUR Acc

ISIN: LU1744628287

Recommended minimum investment horizon

Lower risk Higher risk

. .

1 2 3 4 5 6 7
Main risks of the Fund

EQUITY: The Fund may be affected by stock price variations, the scale of which is dependent on external factors, stock trading volumes or market capitalization.

INTEREST RATE: Interest rate risk results in a decline in the net asset value in the event of changes in interest rates.

CREDIT: Credit risk is the risk that the issuer may default.

CURRENCY: Currency risk is linked to exposure to a currency other than the Fund’s valuation currency, either through direct investment or the use of forward financial instruments.

The Fund presents a risk of loss of capital.

Carmignac Portfolio Patrimoine Europe A EUR Acc

ISIN: LU1744628287
2018 2019 2020 2021 2022 2023 (YTD)
?
Year to date
Carmignac Portfolio Patrimoine Europe A EUR Acc -4.77 % +18.67 % +13.86 % +9.47 % -12.73 % -
Reference Indicator -4.83 % +16.38 % +2.35 % +10.25 % -11.02 % -

Scroll right to see full table

3 years 5 years 10 years
Carmignac Portfolio Patrimoine Europe A EUR Acc +2.84 % +4.21 % -
Reference Indicator +0.14 % +2.15 % -

Scroll right to see full table

Source : Carmignac at 30/12/2022

Maximum subscription fees paid to distributors : 4,00%
Redemption fees : 0,00%
Ongoing Charges : 1.79%
Conversion Fee : 1%
Management fees : 1,50%
Performance fees : 20,00%

Marketing communication. Please refer to the KID, prospectus of the fund before making any final investment decisions. ​​This document is intended for professional clients.

This material may not be reproduced, in whole or in part, without prior authorisation from the Management Company. This material does not constitute a subscription offer, nor does it constitute investment advice. This material is not intended to provide, and should not be relied on for, accounting, legal or tax advice. This material has been provided to you for informational purposes only and may not be relied upon by you in evaluating the merits of investing in any securities or interests referred to herein or for any other purposes. The information contained in this material may be partial information and may be modified without prior notice. They are expressed as of the date of writing and are derived from proprietary and non-proprietary sources deemed by Carmignac to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by Carmignac, its officers, employees or agents.​

Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor).​ The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.​

Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice. The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.​

Morningstar Rating™ : © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.​

Access to the Funds may be subject to restrictions regarding certain persons or countries. This material is not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the material or availability of this material is prohibited. Persons in respect of whom such prohibitions apply must not access this material. Taxation depends on the situation of the individual. The Funds are not registered for retail distribution in Asia, in Japan, in North America, nor are they registered in South America. Carmignac Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Funds have not been registered under the US Securities Act of 1933. The Funds may not be offered or sold, directly or indirectly, for the benefit or on behalf of a «U.S. person», according to the definition of the US Regulation S and FATCA. Company. The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital. ​

The Funds’ prospectus, KIDs, NAV and annual reports are available at www.carmignac.com, or upon request to the Management​ Carmignac Portfolio refers to the sub-funds of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive.​ The French investment funds (fonds communs de placement or FCP) are common funds in contractual form conforming to the UCITS or AIFM Directive under French law

  • UK: This document was prepared by Carmignac Gestion and/or Carmignac Gestion Luxembourg and is being distributed in the UK by Carmignac Gestion Luxembourg UK Branch (Registered in England and Wales with number FC031103, CSSF agreement of 10/06/2013).​ ​FP Carmignac ICVC (the “Company”) is an Investment Company with variable capital incorporated in England and Wales under registered number 839620 and is authorised by the Financial Conduct Authority (the “FCA”) with effect from 4 April 2019 and launched on 15 May 2019. FundRock Partners Limited is the Authorised Corporate Director (the “ACD”) of the Company and is authorised and regulated by the FCA. Registered Office: Second Floor, 52-54 Gracechurch Street, London EC3V 0EH, UK; Registered in England and Wales with number 4162989. Carmignac Gestion Luxembourg SA, UK Branch (Registered in England and Wales with number FC031103, CSSF agreement of 10/06/2013) has been appointed as the Investment Manager and distributor in respect of the Company.

  • In Switzerland: the prospectus, KIDs and annual report are available at www.carmignac.ch, or through our representative in Switzerland, CACEIS (Switzerland), S.A., Route de Signy 35, CH-1260 Nyon. The paying agent is CACEIS Bank, Montrouge, Nyon Branch / Switzerland, Route de Signy 35, 1260 Nyon.

The Management Company can cease promotion in your country anytime. Investors have access to a summary of their rights in English on the following links: UK ; Switzerland ; France ; Luxembourg ; Sweden